SkyGem Acquisition Limited has announced an unconditional mandatory cash offer for Allergy Therapeutics PLC. The Offer Document, which contains the full terms and conditions of the offer and the procedures for acceptance, has been published and sent to Allergy Therapeutics shareholders and persons with information rights. The offer is for 1 pence in cash for each Allergy Therapeutics share, implying a value of approximately £47.91 million for the company's issued and to be issued share capital. The offer represents a discount of 23% to the closing price of 1.30 pence per share on October 18, 2023, and a discount of 84% to the closing price of 6.25 pence per share on April 5, 2023. Shareholders have until 1:00 p.m. (London time) on November 9, 2023, to accept the offer. The offer can be accepted by completing and returning the Form of Acceptance, along with share certificates and/or other documents of title, or by making an electronic acceptance through CREST. Shareholders are advised to seek independent financial advice before making a decision.